R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Insilico Medicine

AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics

Dian DiagnosticsSHE: 300244

Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion

AI

Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection

TakedaTYO: 4502

Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China

Show More